LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Is Increasing Monte Rosa Therapeutics, Inc. (GLUE) Q4 26 Estimate To -0.31 From -0.57 9/15/2025 9:36:11 PM
  • Wedbush Is Raising Monte Rosa Therapeutics, Inc. (GLUE) Q3 26 Estimate To -0.29 From -0.45 9/15/2025 9:35:57 PM
  • Wedbush Is Raising Monte Rosa Therapeutics, Inc. (GLUE) Q2 26 Estimate To -0.31 From -0.46 9/15/2025 9:35:45 PM
  • Wedbush Is Increasing Monte Rosa Therapeutics, Inc. (GLUE) Q1 26 Estimate To -0.36 From -0.55 9/15/2025 9:35:31 PM
  • Wedbush Is Increasing Monte Rosa Therapeutics, Inc. (GLUE) FY 25 Estimate To -0.24 From -0.70 9/15/2025 9:35:15 PM
  • Wedbush Is Raising Monte Rosa Therapeutics, Inc. (GLUE) Q4 25 Estimate To -0.35 From -0.52 9/15/2025 9:35:03 PM
  • Wedbush Is Increasing Monte Rosa Therapeutics, Inc. (GLUE) Q3 25 Estimate To -0.50 From -0.51 9/15/2025 9:34:45 PM
  • Monte Rosa Therapeutics Expands Novartis Partnership To Develop Immune Disease Degraders; Stock Surges 9/15/2025 7:28:41 AM
  • Monte Rosa Collaborates With Novartis To Develop Degraders For Treating Immune-mediated Diseases 9/15/2025 7:03:09 AM
  • Monte Rosa Therapeutics Q2 Net Loss Narrows To $12.3 Mln From $30.3 Mln Prior Year 8/7/2025 8:43:50 AM
  • Monte Rosa Therapeutics Doses First Patient In Phase 1 Study Of MRT-8102 For Multiple Inflammatory Diseases 7/21/2025 7:14:01 AM
  • Monte Rosa Therapeutics: FDA Clears IND Application For MRT-8102 For The Treatment Of Multiple Inflammatory Diseases 6/10/2025 7:14:20 AM
  • Wedbush Is Lowering Monte Rosa Therapeutics, Inc. (GLUE) FY25 Estimate To -1.77 From -0.88 3/20/2025 7:40:09 PM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap